Organigram Global (OGI) Expected to Announce Earnings on Tuesday

Organigram Global (NASDAQ:OGI) is projected to issue its Q1 2026 results before the market opens on Tuesday, February 10th. Analysts expect Organigram Global to post earnings of ($0.01) per share and revenue of $73.3780 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, February 10, 2026 at 8:00 AM ET.

Organigram Global (NASDAQ:OGI) last posted its quarterly earnings results on Tuesday, December 16th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.19). Organigram Global had a negative return on equity of 16.91% and a negative net margin of 9.99%.The company had revenue of $57.53 million during the quarter, compared to the consensus estimate of $73.02 million. On average, analysts expect Organigram Global to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Organigram Global Stock Performance

NASDAQ:OGI opened at $1.51 on Tuesday. The business’s fifty day moving average is $1.69 and its 200 day moving average is $1.66. The firm has a market cap of $204.05 million, a price-to-earnings ratio of -13.73 and a beta of 1.60. Organigram Global has a 52-week low of $0.85 and a 52-week high of $2.24.

Hedge Funds Weigh In On Organigram Global

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE increased its holdings in shares of Organigram Global by 1,678.1% in the 3rd quarter. Bank of America Corp DE now owns 37,357 shares of the company’s stock worth $76,000 after buying an additional 35,256 shares during the last quarter. Tidal Investments LLC increased its stake in Organigram Global by 4.9% in the second quarter. Tidal Investments LLC now owns 2,646,879 shares of the company’s stock valued at $3,573,000 after acquiring an additional 124,356 shares during the last quarter. Finally, Two Sigma Investments LP purchased a new stake in Organigram Global during the third quarter valued at about $907,000. Hedge funds and other institutional investors own 34.63% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on OGI. Canaccord Genuity Group assumed coverage on Organigram Global in a research report on Tuesday, January 27th. They set a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Organigram Global in a report on Monday, December 29th. Finally, Wall Street Zen cut shares of Organigram Global from a “hold” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold”.

About Organigram Global

Organigram Global Inc (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.